Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
4.270
-0.010 (-0.23%)
May 13, 2025, 4:00 PM - Market closed
Profound Medical Revenue
Profound Medical had revenue of $2.62M in the quarter ending March 31, 2025, with 37.23% growth. This brings the company's revenue in the last twelve months to $11.86M, up 75.01% year-over-year. In the year 2024, Profound Medical had annual revenue of $10.68M with 48.35% growth.
Revenue (ttm)
$11.86M
Revenue Growth
+75.01%
P/S Ratio
10.78
Revenue / Employee
$83,535
Employees
142
Market Cap
127.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.68M | 3.48M | 48.35% |
| Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
| Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
| Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
| Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
PROF News
- 5 days ago - Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire
- 14 days ago - Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy - GlobeNewsWire
- 4 weeks ago - Profound Medical AUA 2025 Investor Event Agenda - GlobeNewsWire
- 5 weeks ago - Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 5 weeks ago - PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation - Accesswire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect - Accesswire